| Name | Title | Contact Details |
|---|
Join the YMCA today to access state-of-the-art gyms and pools, free group fitness classes, family programs, child care, swim lessons, and much more.
COREBIO GROUP is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medifacts International, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NLP Logix is an advanced analytics and machine learning data product and services company, which has grown from a vision in 2011 to one of the fastest growing teams of deep learning practitioners. NLP Logix is an experienced team of data scientists who are capable of taking large and disparate data sources and returning actionable and valuable information in a fraction of the time compared to traditional techniques. The company was started by three professionals who worked together at a medical services company developing and applying predictive models and advanced analytics into its workflows. When the founders started NLP Logix, they began competing in international data science contests hosted by Kaggle.com…and started winning. The founders knew that developing algorithms through machine learning was only one piece of the solution, so they began to focus on the practical application of integrating the learned models into a customers` workflow to deliver the most value at the point where decisions were being made. That business model lives today.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.